COSTA MESA, Calif., May 22 CNS Response, Inc.(OTC Bulletin Board: CNSO) reported today the results of a study presented atthe American Psychiatric Association (APA) 161st Annual Meeting by Dr. JamesGreenblatt, M.D., Chief Medical Officer, Walden Behavioral Care InpatientPsychiatry and Eating Disorder Programs. The poster presentation, titled"Referenced-EEG Guided Medication Predictions in Treatment Refractory EatingDisorder Patients," provided a preliminary analysis of a patient-controlledcase series studying the use of Referenced-EEG (rEEG(R)) to facilitate themedication selection for patients with eating disorders and comorbiddepression.
The study of eight female patients, conducted over up to a four-yearperiod, demonstrated that rEEG successfully guided physician selection of eachpatient's medications in the series, leading to a dramatic relief ofdepression and eating disorder symptoms. Successful rEEG-guided predictionsinvolved medications in the anticonvulsant, antidepressant and stimulantclasses, often in combination.
Dr. Greenblatt commented, "Despite the small sample size of this study,the results support the promise of rEEG as an effective tool for determiningmedication programs for treatment refractory patients with eating disordersand depression. The decrease in depressive symptoms, as well as significantimprovement in eating disorders symptoms and weight, for the eight patients inthe trial was striking, considering that, prior to the study, each hadrequired either partial hospitalization or inpatient care, as determined bymanaged behavioral health care reviewers. However, following rEEG medicationrecommendations, hospitalization days for the patients decreased dramatically.Anorexia nervosa is a potentially fatal illness with significant mortality ifearly interventions are not successful. Improved pharmacology, as these casesdemonstrate, could decrease the high morbidity and mortality in patients withdisordered eating."
Primary outcome measures of the study included the 21-item Hamilton Ratingfor Depression Scale (HDRS) and the Clinical Global Improvement Scale (CGI)and the Clinical Global Severity Scale (SGS). Some of the criteria used toassess improvement in the CGI included: body dissatisfaction, drive forthinness, compulsive exercising, binging and purging.
Improvements in both HDRS and CGI scores were evident at 8-weeks,6-months, and 2 years (for 4 patients). The medications selected from rEEGcorrelations involved combinations from many different classes of medications.Stimulant medications in four Eating Disorder patients did not result inappetite suppression or weight loss. These results are consistent with recentfindings that ADHD can predict eating disorder pathology in adolescent girls.
The full poster presentation and analysis of results are available viahttp://www.cnsresponse.com/uploads/assets/0000/0066/rEEGEDPosterCNSR2008.pdf
Greenblatt continued, "Specific patient progress during the studydemonstrated the ability of rEEG to have a real impact on the lives of thosewith severe mental conditions. One anorexia nervosa patient had previouslyreceived five different medication regimes, none of which provided anyimprovement. The patient had been hospitalized on five separate occasionsduring the two years prior to rEEG testing. Based on the rEEG report, wemedicated the patient with a combination of Oxcarbazepine and Duloxetine. Thistreatment combination is outside of the traditional medications we would haveconsidered. In fact, there are no medications that have shown consistentsuccess in treatment of anorexia nervosa. For the 24 months following, thepatient did not require further hospitalization, and at the end of the 24months was rated as 'Normal.'
"The two Bulimia Nervosa patients in the study had seven hospitalizationsbetween them, but neither required further hospital care after b